Diamyd Medical shares learnings from DIAGNODE-3 interim analysis

AstraZeneca reported continued growth in the first half of 2026 and said it remains on track to deliver on its ambition of USD 80 billion in total revenues by 2030.

The offer values PolyPeptide's equity at approximately CHF 1.46 billion.

The European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.

Mendus has signed an agreement with the South Australian Health and Medical Research Institute (SAHMRI) to support preparations for the Phase 2 VITAL-TFR2 trial with the company’s lead product vididencel in chronic myeloid leukemia (CML).

Navinci Diagnostics has initiated a pilot project together with Lumito to evaluate the possibilities of combining the companies’ respective technologies within advanced tissue analysis.

BioArctic’s partner Eisai has announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik) as a starting dose for the treatment of early Alzheimer’s disease.

AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.